CardioExchange Archive

September 29th, 2014

The Implications of PARADIGM-HF for Clinical Practice

Clyde Yancy, MD and Mary Norine Walsh, MD

Clyde Yancy and Mary Norine Walsh offer their perspectives on the much-discussed PARADIGM-HF trial.

---

August 28th, 2014

Predicting PARADIGM-HF, or What to Expect When You’re Expecting

Larry Husten, PHD

Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.

---

March 31st, 2014

Novartis Trial Was Stopped Early Because of a Significant Drop in Cardiovascular Mortality

Larry Husten, PHD

The largest-ever trial in heart failure was stopped early because of a highly statistically significant reduction in cardiovascular mortality, according to one of the trial’s two primary investigators. Earlier today I reported that the PARADIGM-HF trial testing LCZ696, a novel, first-in-class Angiotensin Receptor Neprilysin Inhibitor (ARNI), had been stopped early because the trial had demonstrated a significant reduction in the combined […]

---

March 31st, 2014

Early Success for Novel Novartis Heart Failure Drug

Larry Husten, PHD

A large clinical trial testing a novel compound from Novartis for chronic heart failure has been stopped early for efficacy. In a press release Novartis said the Data Monitoring Committee had recommended early closure of the PARADIGM-HF trial because the trial had demonstrated a significant reduction in the combined primary endpoint of cardiovascular death and heart failure hospitalization. PARADIGM-HF randomized patients with heart failure […]

---